Phase Ib study of anti-CSF-1R antibody emactuzumab in combination with CD40 agonist selicrelumab in advanced solid tumor patients

Phase Ib study of anti-CSF-1R antibody emactuzumab in combination with CD40 agonist selicrelumab in advanced solid tumor patients

Background This phase Ib study evaluated the safety, clinical activity, pharmacokinetics, and pharmacodynamics (PD) of emactuzumab (anti-colony stimulating factor 1 receptor monoclonal antibody (mAb)) in combination with selicrelumab (agonistic cluster of differentiation 40 mAb) in patients with adv...

Full description

Saved in:
Bibliographic Details
Main Authors: Jean-Marie Michot, Wolfgang Jacob, Francesca Michielin, Martin Weisser, Dmitriy Zamarin, Jean-Pascal Machiels, Anna-Maria Jegg, Dominik Rüttinger, Konstanty Korski, Jean-Pierre Delord, Carlos Gomez-Roca, Tara Mitchell, Gaetan Catala, Lauriane Eberst, Michael A Cannarile, Carl Watson, Galina Babitzki, Irina Klaman, Priscila Teixeira, Sabine Hoves, Carola Ries, Georgina Meneses-Lorente, Randolph Christen, Philippe Cassier
Format: Article
Language:English
Published: BMJ Publishing Group 2020-10-01
Series:Journal for ImmunoTherapy of Cancer
Online Access:https://jitc.bmj.com/content/8/2/e001153.full
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://jitc.bmj.com/content/8/2/e001153.full

Similar Items